TD Cowen analyst Jonna Kim raised the firm’s price target on Hims & Hers to $25 from $15 and keeps a Buy rating on the shares. The firm believes the company provides compelling value underpinned by effective products and services to consumers who seek convenience and personalization in healthcare treatments and they see robust growth in subscribers and churn rates improving over time.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers now down 15% to $18.36 following Hunterbrook report
- Hims & Hers falls after Hunterbrook Media report on GLP-1 drug sales
- Hims & Hers price target raised to $23 from $14 at Jefferies
- Hims and Hers Health call volume above normal and directionally bullish
- Hims & Hers price target raised to $26 from $22 at BofA